• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Erasca Inc. (Amendment)

    2/13/24 8:24:49 PM ET
    $ERAS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ERAS alert in real time by email
    SC 13G/A 1 d743522dsc13ga.htm SC 13G/A SC 13G/A

     

     

    United States

    Securities and Exchange Commission

    Washington, D.C. 20549

     

     

    Schedule 13G

    (Rule 13d-102)

    Information to be Included in Statements Filed Pursuant

    to § 240.13d-1(b), (c) and (d) and Amendments Thereto Filed

    Pursuant to § 240.13d-2

    UNDER THE SECURITIES EXCHANGE ACT OF 1934

    (Amendment No. 2)*

     

     

    Erasca, Inc.

    (Name of Issuer)

    Common Stock

    (Title of Class of Securities)

    29479A108

    (CUSIP Number)

    December 31, 2023

    (Date of Event Which Requires Filing of this Statement)

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☐ Rule 13d-1(b)

    ☐ Rule 13d-1(c)

    ☒ Rule 13d-1(d)

     

    *

    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     


    CUSIP No. 29479A108    Schedule 13G    Page 1 of 8

     

     1   

    Names of Reporting Persons

     

    City Hill, LLC

     2   

    Check the Appropriate Box if a Member of a Group

    (a)  ☐  (b) ☐

     

     3   

    SEC Use Only

     

     4   

    Citizenship or Place of Organization

     

    Delaware

    Number of Shares Beneficially  Owned by Each Reporting Person With     5   

    Sole Voting Power

     

    0

        6   

    Shared Voting Power

     

    12,899,360

        7   

    Sole Dispositive Power

     

    0

        8   

    Shared Dispositive Power

     

    12,899,360

     9   

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    12,899,360

    10   

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares

     

    Not Applicable

    11   

    Percent of Class Represented by Amount in Row 9

     

    8.5%

    12   

    Type of Reporting Person

     

    OO


    CUSIP No. 29479A108    Schedule 13G    Page 2 of 8

     

     1   

    Names of Reporting Persons

     

    Jonathan E. Lim

     2   

    Check the Appropriate Box if a Member of a Group

    (a) ☐  (b) ☐

     

     3   

    SEC Use Only

     

     4   

    Citizenship or Place of Organization

     

    Canada

    Number of Shares Beneficially  Owned by Each Reporting Person With     5   

    Sole Voting Power

     

    770,500

        6   

    Shared Voting Power

     

    32,355,576

        7   

    Sole Dispositive Power

     

    770,500

        8   

    Shared Dispositive Power

     

    32,355,576

     9   

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    33,126,076

    10   

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares

     

    Not Applicable

    11   

    Percent of Class Represented by Amount in Row 9

     

    21.8%

    12   

    Type of Reporting Person

     

    IN


    CUSIP No. 29479A108    Schedule 13G    Page 3 of 8

     

     1   

    Names of Reporting Persons

     

    Conyee T. Lim

     2   

    Check the Appropriate Box if a Member of a Group

    (a) ☐  (b) ☐

     

     3   

    SEC Use Only

     

     4   

    Citizenship or Place of Organization

     

    United States

    Number of Shares Beneficially  Owned by Each Reporting Person With     5   

    Sole Voting Power

     

    0

        6   

    Shared Voting Power

     

    19,456,216

        7   

    Sole Dispositive Power

     

    0

        8   

    Shared Dispositive Power

     

    19,456,216

     9   

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    19,456,216

    10   

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares

     

    Not Applicable

    11   

    Percent of Class Represented by Amount in Row 9

     

    12.9%

    12   

    Type of Reporting Person

     

    IN


    CUSIP No. 29479A108    Schedule 13G    Page 4 of 8

     

    ITEM 1.

    (a)  Name of Issuer:

    Erasca, Inc. (the “Issuer”).

     

      (b)

    Address of Issuer’s Principal Executive Offices:

    3115 Merryfield Row, Suite 300, San Diego, CA 92121

     

    ITEM 2.

    (a)  Name of Person Filing:

    Each of the following is hereinafter individually referred to as a “Reporting Person” and collectively as the “Reporting Persons.” This statement is filed on behalf of:

    City Hill, LLC

    Jonathan E. Lim

    Conyee T. Lim

     

      (b)

    Address or Principal Business Office:

    The principal business address of the Reporting Persons is c/o Erasca, Inc., 3115 Merryfield Row, Suite 300, San Diego, CA 92121.

     

      (c)

    Citizenship of each Reporting Person is:

    City Hill, LLC is organized under the laws of the State of Delaware. Jonathan E. Lim is a citizen of Canada and Conyee T. Lim is a citizen of the United States.

     

      (d)

    Title of Class of Securities:

    Common stock, $0.0001 par value per share (“Common Stock”).

     

      (e)

    CUSIP Number:

    29479A108

     

    ITEM 3.

    Not applicable.


    CUSIP No. 29479A108    Schedule 13G    Page 5 of 8

     

    ITEM 4.

    Ownership.

    (a-c)

    The ownership information presented below represents beneficial ownership of Common Stock as of December 31, 2023, based upon 151,087,038 shares of Common Stock outstanding as of November 2, 2023, as disclosed in the Issuer’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 9, 2023.

     

    Reporting Person   

    Amount

    beneficially 

    owned

        

    Percent

    of class:

       

    Sole

    power

    to vote

    or to

    direct

    the vote:

        

    Shared

    power to

    vote or to

    direct the

    vote:

        

    Sole

    power to

    dispose or

    to direct

    the

    disposition

    of:

        

    Shared

    power to

    dispose or

    to direct

    the

    disposition

    of:

     

    City Hill, LLC

         12,899,360        8.5 %      0        12,899,360        0        12,899,360  

    Jonathan E. Lim

         33,126,076        21.8 %      770,500        32,355,576        770,500        32,355,576  

    Conyee T. Lim

         19,456,216        12.9 %      0        19,456,216        0        19,456,216  

    City Hill, LLC is the record holder of 12,899,360 shares of Common Stock. Jonathan E. Lim is the Managing Partner of City Hill, LLC and as a result may be deemed to share beneficial ownership of the shares of Common Stock held of record by City Hill, LLC. Jonathan E. Lim may be deemed to beneficially own 770,500 shares of Common Stock underlying stock options exercisable on or within 60 days of December 31, 2023.

    In addition, Jonathan E. Lim and Conyee T. Lim serve as co-trustees of a family trust that is the record holder of 19,456,216 shares of Common Stock. As a result, each of Jonathan E. Lim and Conyee T. Lim may be deemed to share beneficial ownership of the shares of Common Stock held of record by such trust.

     

    ITEM 5.

    Ownership of Five Percent or Less of a Class.

    Not applicable.

     

    ITEM 6.

    Ownership of More than Five Percent on Behalf of Another Person.

    Not applicable.

     

    ITEM 7.

    Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company.

    Not applicable.


    CUSIP No. 29479A108    Schedule 13G    Page 6 of 8

     

    ITEM 8.

    Identification and Classification of Members of the Group.

    Not applicable.

     

    ITEM 9.

    Notice of Dissolution of Group.

    Not applicable.

     

    ITEM 10.

    Certification.

    Not applicable.


    CUSIP No. 29479A108    Schedule 13G    Page 7 of 8

     

    SIGNATURE

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Date: February 13, 2024

     

    City Hill, LLC
    By:   /s/ Jonathan E. Lim, M.D.
    Name:   Jonathan E. Lim, M.D.
    Title:   Managing Partner

     

    Jonathan E. Lim
    /s/ Jonathan E. Lim, M.D.
    Conyee T. Lim
    /s/ Conyee T. Lim, M.D.


    CUSIP No. 29479A108    Schedule 13G    Page 8 of 8

     

    LIST OF EXHIBITS

     

    Exhibit No.

      

    Description

    99    Joint Filing Agreement (previously filed).
    Get the next $ERAS alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ERAS

    DatePrice TargetRatingAnalyst
    6/4/2026$16.00Underperform → Neutral
    BofA Securities
    1/27/2026$16.00Outperform
    Mizuho
    1/7/2026$5.00Overweight
    Piper Sandler
    10/16/2025$4.00Buy
    Stifel
    9/3/2025Buy → Underperform
    BofA Securities
    8/18/2025$2.00Overweight → Equal-Weight
    Morgan Stanley
    3/26/2025$5.00Outperform
    Raymond James
    11/18/2024$6.00Buy
    Jefferies
    More analyst ratings

    $ERAS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Erasca upgraded by BofA Securities with a new price target

    BofA Securities upgraded Erasca from Underperform to Neutral and set a new price target of $16.00

    6/4/26 8:39:34 AM ET
    $ERAS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Mizuho resumed coverage on Erasca with a new price target

    Mizuho resumed coverage of Erasca with a rating of Outperform and set a new price target of $16.00

    1/27/26 8:45:40 AM ET
    $ERAS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Piper Sandler initiated coverage on Erasca with a new price target

    Piper Sandler initiated coverage of Erasca with a rating of Overweight and set a new price target of $5.00

    1/7/26 9:10:17 AM ET
    $ERAS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ERAS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Erasca to Present at the Jefferies Global Healthcare Conference

    SAN DIEGO, May 27, 2026 (GLOBE NEWSWIRE) -- Erasca, Inc. (NASDAQ:ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced its participation in the Jefferies Global Healthcare Conference being held at the Marriott Marquis in New York, NY. Management will participate in a fireside chat on Wednesday, June 3, 2026, at 3:10 pm Eastern Time and will also participate in one-on-one investor meetings. A live audio webcast of the event will be available online at Erasca.com/events. An archived replay of the event will be available for 30 days following the webcas

    5/27/26 8:00:00 AM ET
    $ERAS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Erasca Reports First Quarter 2026 Business Updates and Financial Results

    Robust monotherapy efficacy and generally well-tolerated safety results observed during dose escalation for ERAS-0015 in both KRAS G12X NSCLC and PDAC reinforce best-in-class potential across RAS-targeted agents ERAS-0015 monotherapy expansion and combination dose escalation data expected in H1 2027; ERAS-4001 Phase 1 preliminary monotherapy data expected in H2 2026 Robust balance sheet with cash, cash equivalents, and marketable securities of $409 million as of March 31, 2026 expected to fund operations into H2 2028 SAN DIEGO, May 11, 2026 (GLOBE NEWSWIRE) -- Erasca, Inc. (NASDAQ:ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, an

    5/11/26 4:01:00 PM ET
    $ERAS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Erasca Announces Clinical Trial Collaboration and Supply Agreement with Merck to Evaluate ERAS-0015 in Combination with KEYTRUDA® (Pembrolizumab)

    SAN DIEGO, May 11, 2026 (GLOBE NEWSWIRE) -- Erasca, Inc. (NASDAQ:ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced a clinical trial collaboration and supply agreement (CTCSA) with Merck, known as MSD outside of the United States and Canada. This agreement supports a clinical proof-of-concept study, AURORAS-1, evaluating the pan-RAS molecular glue ERAS-0015 in combination with KEYTRUDA® (pembrolizumab), Merck's anti-PD-1 therapy, for the treatment of patients with RAS-mutant (RASm) solid tumors. Erasca is sponsoring the study, and Merck is supplyi

    5/11/26 7:00:00 AM ET
    $ERAS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ERAS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Garner Ebun

    4 - Erasca, Inc. (0001761918) (Issuer)

    4/3/26 9:00:03 AM ET
    $ERAS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Medical Officer Morris Shannon exercised 20,000 shares at a strike of $1.70 and sold $300,760 worth of shares (20,000 units at $15.04) (SEC Form 4)

    4 - Erasca, Inc. (0001761918) (Issuer)

    3/6/26 9:00:03 AM ET
    $ERAS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Chairman & CEO Lim Jonathan E

    4 - Erasca, Inc. (0001761918) (Issuer)

    1/30/26 9:05:03 AM ET
    $ERAS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ERAS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Casdin Alexander W. bought $181,920 worth of shares (80,000 units at $2.27) (SEC Form 4)

    4 - Erasca, Inc. (0001761918) (Issuer)

    5/22/24 6:57:45 PM ET
    $ERAS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Start Valerie Denise Harding bought $18,480 worth of shares (10,000 units at $1.85) (SEC Form 4)

    4 - Erasca, Inc. (0001761918) (Issuer)

    12/8/23 9:10:12 AM ET
    $ERAS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Lim Jonathan E bought $1,696,179 worth of shares (1,000,000 units at $1.70) (SEC Form 4)

    4 - Erasca, Inc. (0001761918) (Issuer)

    12/6/23 7:41:47 PM ET
    $ERAS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ERAS
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by Erasca Inc.

    SCHEDULE 13G/A - Erasca, Inc. (0001761918) (Subject)

    5/15/26 4:34:32 PM ET
    $ERAS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Erasca Inc.

    SCHEDULE 13G/A - Erasca, Inc. (0001761918) (Subject)

    5/15/26 10:06:32 AM ET
    $ERAS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SCHEDULE 13G filed by Erasca Inc.

    SCHEDULE 13G - Erasca, Inc. (0001761918) (Subject)

    5/15/26 8:20:31 AM ET
    $ERAS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ERAS
    Leadership Updates

    Live Leadership Updates

    View All

    Oncology Innovation Just Hit a Turning Point -- Here's What to Watch

    USA News Group News CommentaryIssued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, June 30, 2025 /PRNewswire/ -- USA News Group News Commentary – The oncology landscape is being pulled in two directions. On one hand, U.S. cancer death rates continue to decline. On the other, global cases are expected to rise sharply—while early-onset diagnoses in younger patients are climbing at a troubling pace. At the same time, proposed federal budget cuts threaten to slash funding for the National Cancer Institute by up to 40%, raising concerns about the future of publicly funded research. With public resources under pressure, much of the innovation burden is shifting to the private sector, where a

    6/30/25 11:02:00 AM ET
    $ARAY
    $CLRB
    $ERAS
    Medical/Dental Instruments
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Biotechnology: Biological Products (No Diagnostic Substances)

    Erasca Appoints Jean Liu to its Board of Directors

    SAN DIEGO, April 27, 2022 (GLOBE NEWSWIRE) -- Erasca, Inc. (NASDAQ:ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced the appointment of Jean Liu to its board of directors and to its audit committee. Ms. Liu brings over 20 years of professional experience advising biopharmaceutical companies on corporate, intellectual property, compliance, and general legal matters. "Jean Liu has been a seasoned executive with Seagen during its transformation into a leading global, multiproduct oncology company, and she also is one of the most strategic busine

    4/27/22 8:00:00 AM ET
    $ERAS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Erasca Strengthens Leadership Team with Two Key Executive Appointments

    Lisa Tesvich-Bonora appointed as Chief People Officer Robert Shoemaker promoted to Senior Vice President of Research SAN DIEGO, Jan. 18, 2022 (GLOBE NEWSWIRE) -- Erasca, Inc. (NASDAQ:ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced the appointment of Lisa Tesvich-Bonora as Chief People Officer and the promotion of Robert Shoemaker to Senior Vice President of Research. "I am thrilled to welcome Lisa to the Erasca family. With over two decades of experience in creating collaborative and engaging environments where employees can thrive, she bring

    1/18/22 8:00:00 AM ET
    $ERAS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ERAS
    Financials

    Live finance-specific insights

    View All

    Erasca Announces Positive Preliminary Phase 1 Dose Escalation Data for Potentially Best-in-Class Pan-RAS Molecular Glue ERAS-0015 in KRAS-Mutant Solid Tumors

    Robust monotherapy efficacy in KRAS G12X NSCLC: 62% uORR in 2L+ and 75% uORR in post-ICI/platinum 2/3L at 16-32 mg QD PAD, and 64% uORR in 2L+ at 24-32 mg QD RDE Robust monotherapy efficacy in 2L KRAS G12X PDAC: 40% uORR at 16-32 mg QD PAD, 42% uORR at 24-32 mg QD RDE, and 50% uORR at 32 mg QD Monotherapy generally well-tolerated with mostly low-grade AEs, no DLTs as of DCO, and low rate of dose reductions and no discontinuations due to TRAEs Preliminary data suggest ERAS-0015 may combine safely with standard-of-care doses of panitumumab with no DLTs as of DCO (N=3) and 1/1 uPR in CRC Well-behaved PK, with dose-dependent increase in PK exposure up to MAD of 40 mg QD and no exposure plate

    4/27/26 4:01:00 PM ET
    $ERAS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Erasca to Host Conference Call and Webcast to Discuss Preliminary Phase 1 Dose Escalation Data for Potentially Best-in-Class Pan-RAS Molecular Glue ERAS-0015

    SAN DIEGO, April 27, 2026 (GLOBE NEWSWIRE) -- Erasca, Inc. (NASDAQ:ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced that the Company will host a conference call and webcast to discuss preliminary Phase 1 dose escalation data for its potentially best-in-class pan-RAS molecular glue ERAS-0015 in patients with RAS-mutant solid tumors today, Monday, April 27, 2026, at 4:30 pm ET. Conference Call and Webcast InformationErasca will hold a conference call and webcast Monday, April 27, 2026, at 4:30 pm ET. The webcast link for the conference call is her

    4/27/26 8:30:00 AM ET
    $ERAS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Erasca Announces Strategic In-Licensing of RAS-Targeting Franchise

    Pan-RAS molecular glue ERAS-0015 and pan-KRAS inhibitor ERAS-4001 are potent, oral inhibitors with potential best-in-class profiles in RASm solid tumors Pipeline prioritization and workforce restructuring sharpens focus on programs targeting the highest unmet needs and with highest probability of success Priced concurrent $160 million equity offering Erasca to host conference call and webcast Friday, May 17, 2024 at 8:30 am ET SAN DIEGO, May 16, 2024 (GLOBE NEWSWIRE) -- Erasca, Inc. (NASDAQ:ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today anno

    5/16/24 8:02:00 PM ET
    $ERAS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ERAS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Erasca Inc.

    SC 13G/A - Erasca, Inc. (0001761918) (Subject)

    11/14/24 5:13:04 PM ET
    $ERAS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Erasca Inc.

    SC 13G/A - Erasca, Inc. (0001761918) (Subject)

    11/14/24 4:04:32 PM ET
    $ERAS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Erasca Inc.

    SC 13G - Erasca, Inc. (0001761918) (Subject)

    11/14/24 1:28:34 PM ET
    $ERAS
    Biotechnology: Pharmaceutical Preparations
    Health Care